Comparison · NCT04070326-acad77a5
Lanadelumab 150 mg: Age 2 to <6 Years vs Lanadelumab 150 mg: Age 6 to <12 Years: Number of Participants With Clinically Significant Vital Signs Measurements
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Lanadelumab 150 mg: Age 2 to <6 Years vs Lanadelumab 150 mg: Age 6 to <12 Years: Number of Participants With Clinically Significant Vital Signs Measurements. Trial comparisons, record NCT04070326-acad77a5. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04070326-acad77a5
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.49 | wilson | |
| Risk in group 2 | 0 | 0 | 0.184 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.184 | 0.49 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Lanadelumab 150 mg: Age 2 to <6 Years | Participants aged 2 to \<6 years received lanadelumab SC injection at a dose of 150 mg for q4wks over 52-week Treatment Period (26-week Treatment Period A and 26-week Treatment Period B). | 0 | 4 | OG000 |
| Group 2 | Lanadelumab 150 mg: Age 6 to <12 Years | Participants aged 6 to \<12 years received lanadelumab SC injection at a dose of 150 mg for q2wks over 52-week Treatment Period (26-week Treatment Period A and 26-week Treatment Period B). Participants could switch to a dosing regimen of 150 mg q4wks in Treatment Period B at the investigator's discretion and sponsor's medical monitor approval, if they were well controlled (e.g., attack free) for 26 weeks with lanadelumab treatment in this study. | 0 | 17 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Clinically Significant Vital Signs Measurements
- Description
- Vital signs included blood pressure, heart rate, body temperature, and respiratory rate.
- Time frame
- Up to approximately 115 weeks
- Population
- The Safety Analysis Set consisted of all participants who received study drug.
Source ClinicalTrials.gov
Trial
- Title
- A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children
- NCT number
- NCT04070326
- Phases
- PHASE3
- Conditions
- Hereditary Angioedema
- Interventions
- Lanadelumab
- Lead sponsor
- Shire
- Results first posted
- 2022-05-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04070326?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04070326-acad77a5